I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).

NCT03939689 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Prostate Cancer
Castration-resistant Prostate Cancer
Prostatic Neoplasm
Cancer of the Prostate
Progressive mCRPC

Interventions

DRUG: I-131-1095
DRUG: Enzalutamide

Sponsor

Progenics Pharmaceuticals, Inc.